Bronchiolitis Obliterans Clinical Trial
Official title:
Lung Clearance Index (LCI) and Bronchial Inflammation in Patients With Bronchiolitis Obliterans (BO)
The investigators here compare lung function parameters (RV, RV/TLC and FEF75) with the results of the Lung Clearance index (LCI) . Further this study evaluates bronchial inflammatory markers in 20 patients with bronchiolitis obliterans at the age of 6 to 28 years compared with an age- and sex-matched control group. The investigators will perform a pulmonary function test (body plethysmography with DLCO) and compare the results with the LCI. Further we will measure the fraction of exhaled nitric oxide (FeNO) and draw a blood sample to determine the level of systemic inflammation. Finally induced sputum is collected and a cell count is performed, and cells and supernatants are analyzed for inflammatory markers. This study will set baseline markers for future interventional studies.
The purpose of this study is to compare lung function values with the Lung clearance index
of 20 Patients with Bronchiolitis obliterans aged between 6 up to 28 years. Further we aim
to compare the bronchial Inflammation between the patients and a reference group with
similar age conditions to determine possible outcome-parameters for following interventional
studies.
The sputum samples will be processed and quantitatively analyzed to get a profile of the
cytological composition.
(Sputum and serum samples are analyzed by quantitative real-time polymerase chain reaction
(PCR) (qRT-PCR) and by cytometric bead assay (CBA).)
Methods and Work Programme:
- Measurement of nitric oxide in expired air (FeNO)
- Lung function testing with spirometry and body plethysmography
- Lung clearance index (LCI)
- Bronchodilation
- Blood test: blood count, CRP, RAST, serum inflammatory mediators, (genetic markers of
the non-specific pulmonary defense system)
- Induced sputum for inflammatory mediators and microbiological investigations
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03603899 -
Hp129 Xenon Imaging and BOS in Lung Transplantation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04098445 -
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
|
||
| Completed |
NCT02441413 -
Transplant Optimization Using Functional Imaging (TROFI)
|
N/A | |
| Recruiting |
NCT02543073 -
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
|
Phase 1/Phase 2 | |
| Terminated |
NCT01432080 -
Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant
|
Phase 2 | |
| Recruiting |
NCT00163696 -
Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease
|
N/A | |
| Completed |
NCT00029328 -
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
|
Phase 1/Phase 2 | |
| Terminated |
NCT01163786 -
A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
|
Phase 2 | |
| Recruiting |
NCT02627833 -
Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO
|
N/A | |
| Completed |
NCT01211509 -
Montelukast in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
| Completed |
NCT01212406 -
Vitamin D in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
| Completed |
NCT00701922 -
Surveillance Study of Viral Infections Following Lung Transplantation
|
N/A | |
| Completed |
NCT00141726 -
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT05922761 -
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
|
Phase 2 | |
| Recruiting |
NCT05881538 -
High Intensity Intervallic Training in Children With Bronchiolitis Obliterans
|
N/A | |
| Terminated |
NCT04655508 -
Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation
|
Phase 3 | |
| Withdrawn |
NCT02109237 -
Sleep Disorders in Bronchiolitis Obliterans Syndrome 2&3
|
N/A | |
| Completed |
NCT01327248 -
Clinical Status and Bronchial Inflammation in Patients With Bronchiolitis Obliterans
|
N/A | |
| Recruiting |
NCT05932316 -
Evaluating Bronchodilator Response in Patients With Bronchiectasis
|
N/A | |
| Active, not recruiting |
NCT03656926 -
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)
|
Phase 3 |